Quantum physics is a relatively new field built since the beginning of the 20th century, but we have used MRI (nuclear magnetic resonance equipment) and lasers used for close examinations in hospitals, and semiconductors mounted on computers. Supports the technology that supports the daily life of people.QunaSys was established to bring out the quantum physics that has been active behind the scenes to the front stage, and to make use of quantum properties to realize technologies that could not be achieved with existing technologies.
Rege Nephro Co., Ltd. engages in the research and development, production, and marketing of renal disease therapeutics using nephron progenitor cells. It also produces kidney organoids capable of nephrotoxicity screening for drug discovery in applied research. The company was founded in 2019 and is based in Kyoto, Japan.
Luxonus is engaged in the development of advanced imaging devices utilizing photoacoustic technology. This innovative approach allows for the early detection and diagnosis of diseases by producing ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. The device operates safely and effectively without exposing patients to harmful radiation, as it combines optical and ultrasonic waves. By providing detailed insights into the onset of diseases, the healing process, and health conditions before and after illness, Luxonus aims to enhance the diagnostic capabilities available to healthcare professionals.
Developer of high-intensity focused ultrasound therapy systems designed to revolutionize medical therapy for the treatment of cancer patients. The company offers precise tissue targeting and real-time imaging capabilities, enabling healthcare professionals specializing in oncology and non-invasive surgery to deliver effective treatments with enhanced accuracy and patient comfort.
Alchemedicine is a company focused on drug discovery aimed at addressing diseases with significant unmet medical needs. Utilizing unique technologies and innovative approaches, Alchemedicine develops new drug candidates even in challenging areas where traditional drug discovery may struggle. The company’s services are designed to expedite the process of bringing effective medications to patients, ensuring that new treatments are available as quickly as possible. Through its commitment to advancing medical solutions, Alchemedicine plays a vital role in the fight against diseases that lack adequate therapeutic options.
Developer of a novel drug designed to target treatment in neuroscience, oncology, and infectious diseases. The company develops drugs to cure dementia, peripheral amyloidosis, Alzheimer's, and cancer, enabling clients to get therapeutic services to cure such diseases.
Epsilon Molecular Engineering Inc. is a biotechnology research and development company based in Saitama, Japan. Founded in 2016, the company specializes in drug discovery and development, focusing on antibodies and peptides. In addition to its core research and development activities, Epsilon Molecular Engineering provides contracted research services in biotechnology, consulting, and bioinformatics information management.
A*Quantum is a company focused on developing quantum computer software. It aims to accelerate digital transformation for businesses by leveraging a combination of quantum computing technology, mathematical optimization, and artificial intelligence. A*Quantum's mission is to address complex social issues that conventional science struggles to solve, providing researchers and end-users with applications and libraries to facilitate problem-solving. Through its innovative approach, the company contributes to the advancement of technology and aims to support significant developments in various fields.
Periotherapia is a Drug discovery business with triple negative breast cancer as the first indication. Periotherapia aims to selectively inhibit only ASV that is involved in pathogenesis without inhibiting physiological ASV in chronic diseases such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. is.
Menou Inc. is engage in AI introduction and technology services business. The company was founded in 2019 and is based in Tokyo, Japan.
Developer of a novel drug designed to target treatment in neuroscience, oncology, and infectious diseases. The company develops drugs to cure dementia, peripheral amyloidosis, Alzheimer's, and cancer, enabling clients to get therapeutic services to cure such diseases.
Numab Therapeutics AG is a biotechnology company based in Wädenswil, Switzerland, founded in 2011. The company specializes in developing antibody-based therapeutics aimed at treating severe diseases, including cancer and chronic inflammation. Numab utilizes a unique plug-and-play platform that enhances the predictability of the drug discovery process, allowing for the efficient creation of multispecific biotherapeutics. Its research pipeline encompasses various therapeutic areas, including inflammatory bowel disease, immuno-oncology, autoimmunity, and inflammation.
TNAX Biopharma is a developer of pharmaceuticals drugs intended to improve the quality of life of patients.The company provides novel antibody therapeutics for unmet medical needs of patients with intractable diseases, thus providing patients therapeutics around the world through drug discovery innovation.
Luxonus is engaged in the development of advanced imaging devices utilizing photoacoustic technology. This innovative approach allows for the early detection and diagnosis of diseases by producing ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. The device operates safely and effectively without exposing patients to harmful radiation, as it combines optical and ultrasonic waves. By providing detailed insights into the onset of diseases, the healing process, and health conditions before and after illness, Luxonus aims to enhance the diagnostic capabilities available to healthcare professionals.
Alchemedicine is a company focused on drug discovery aimed at addressing diseases with significant unmet medical needs. Utilizing unique technologies and innovative approaches, Alchemedicine develops new drug candidates even in challenging areas where traditional drug discovery may struggle. The company’s services are designed to expedite the process of bringing effective medications to patients, ensuring that new treatments are available as quickly as possible. Through its commitment to advancing medical solutions, Alchemedicine plays a vital role in the fight against diseases that lack adequate therapeutic options.
Epsilon Molecular Engineering Inc. is a biotechnology research and development company based in Saitama, Japan. Founded in 2016, the company specializes in drug discovery and development, focusing on antibodies and peptides. In addition to its core research and development activities, Epsilon Molecular Engineering provides contracted research services in biotechnology, consulting, and bioinformatics information management.
Cyfuse Biomedical develops tissue fabrication systems and cell-based products in Japan and internationally. The company offers 3D BioFabrication systems and related consumables; develops and licenses 3D tissue products for therapeutic and drug development use; and engages in contract manufacturing of 3D tissue products for research purposes.
Its products applications include blood vessel grafts for blood access of hemodialysis patients or coronary artery bypass grafts; cardiac grafts for drug toxicology screening or supplemental therapy of myocardial infarction; cartilage grafts for plastic surgery or reconstruction; and hepatocyte grafts for drug metabolism screening or in-vivo production of clotting factors in the treatment of hemophilia.
Cyfuse Biomedical was founded in 2010 and is based in Tokyo, Japan.
Veritas In Silico is a start-up to research and sales of pharmaceuticals.Veritas In Silico, target partial structures in messenger RNA (mRNA) by exploring the true form of RNA, the origin of life, based on in silico (computer-based computational science) technology Established a drug discovery system with a completely new concept.This mRNA-targeted drug has the potential to be applied to any disease, including those for which it has been difficult to develop therapeutic drugs using conventional protein-based drug discovery. Therefore, it is expected to be a favorite for next-generation drug discovery that will cause a paradigm shift in the pharmaceutical industry.
TNAX Biopharma is a developer of pharmaceuticals drugs intended to improve the quality of life of patients.The company provides novel antibody therapeutics for unmet medical needs of patients with intractable diseases, thus providing patients therapeutics around the world through drug discovery innovation.
Ball Wave Inc. specializes in the development, manufacturing, and sale of advanced sensors, including trance moisture sensors, mini sensors, and ball surface acoustic wave gas sensors. Founded in 2015 and based in Sendai, Japan, the company focuses on innovative sensor technology that enables high-speed and sensitive detection of various chemical attributes, such as moisture and hydrogen, at the nanoscale. Their spherical sensors and analyzers serve as essential tools for accurately monitoring environmental conditions, effectively functioning as an advanced detection system for a range of gases and materials.
CellGenTech, Inc. is a biopharmaceutical company based in Chiba, Japan, focused on the research and development of gene therapies and regenerative medicine. Founded in 2003, the company specializes in adipocyte-based technologies to create innovative gene and cell therapies. CellGenTech is currently conducting translational clinical research targeting LCAT deficiency, with plans to extend its therapeutic applications to other rare diseases. The company offers protein supplemental therapy solutions for various conditions, including hereditary and orphan diseases, intractable diseases such as lysosomal disorders and hemophilia, as well as diabetic and cardiovascular diseases. Through the use of genetically modified human adipocytes, CellGenTech aims to replenish essential enzymes and proteins, providing new treatment options for patients with specific medical needs.
Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, founded in 2005. The company specializes in the development of artificial chromosome technologies, which are utilized primarily for life sciences applications. By employing artificial chromosome vectors, Chromocenter focuses on advancing drug discovery processes, particularly in the field of medical pharmaceuticals. Its innovative approach aims to enhance the efficacy and efficiency of biopharmaceutical manufacturing, positioning the company at the forefront of next-generation therapeutic development.
Cyfuse Biomedical develops tissue fabrication systems and cell-based products in Japan and internationally. The company offers 3D BioFabrication systems and related consumables; develops and licenses 3D tissue products for therapeutic and drug development use; and engages in contract manufacturing of 3D tissue products for research purposes.
Its products applications include blood vessel grafts for blood access of hemodialysis patients or coronary artery bypass grafts; cardiac grafts for drug toxicology screening or supplemental therapy of myocardial infarction; cartilage grafts for plastic surgery or reconstruction; and hepatocyte grafts for drug metabolism screening or in-vivo production of clotting factors in the treatment of hemophilia.
Cyfuse Biomedical was founded in 2010 and is based in Tokyo, Japan.
Stem Cell & Device Laboratory, Inc. focuses on research and development, manufacturing, and sales of cellular products, devices, and integrated cell-material products specifically designed for drug discovery applications. The company specializes in creating innovative scaffold materials that enhance cell functionality and compatibility, leveraging advanced micro-engineering and nanofabrication technologies. Founded in 2014 and headquartered in Kyoto, Japan, Stem Cell & Device Laboratory is dedicated to advancing cell applications that contribute to a healthier society.
Veritas In Silico is a start-up to research and sales of pharmaceuticals.Veritas In Silico, target partial structures in messenger RNA (mRNA) by exploring the true form of RNA, the origin of life, based on in silico (computer-based computational science) technology Established a drug discovery system with a completely new concept.This mRNA-targeted drug has the potential to be applied to any disease, including those for which it has been difficult to develop therapeutic drugs using conventional protein-based drug discovery. Therefore, it is expected to be a favorite for next-generation drug discovery that will cause a paradigm shift in the pharmaceutical industry.
Mitsufuji Corporation manufactures a silver plated yarn that has electric field, electro static discharge, anti-bacterial, and thermal effects. It can be used in knitted and woven fabrics. The company was founded in 1956 and is headquartered in Kyoto, Japan.
Anaeropharma Science, Inc. is a biopharmaceutical company based in Chiyoda, Japan, founded in 2004. The company specializes in the development of therapeutics aimed at treating solid cancers characterized by hypoxic environments. Utilizing its proprietary platform technology, which involves recombinant Bifidobacterium, Anaeropharma Science develops innovative solutions including APS001F for solid tumors, anticancer drugs in the immuno-oncology sector, and treatments for ischemia such as FGF2. The company's approach leverages genetically enhanced bacteria that thrive in the low-oxygen conditions typical of solid tumors, where they convert systemically administered pro-drugs into cytotoxic agents, thereby providing healthcare professionals with effective and safe therapeutic options for cancer and related hypoxic conditions.
NanoMist Technologies engages with R&D, design, and sells machines in the areas such as alcoholic beverages and food enrichment, fragrance extraction, chemical purification process, wastewater management, and deodorization process. NanoMist Technologies manufactures and sells machines such as ultrasonic atomization machine, deodorization machine, hot spring water concentration machine, solvent recovery machine, VOCs recovery machine, and granular material production machine.
Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
eSep, Inc. is a company based in Kyoto, Japan, that specializes in the design, development, and sale of membrane-based separation technology. The company focuses on microporous ceramic membranes, including zeolite and silica membranes, as well as membrane reactors and process simulation. eSep's innovative technology aims to simplify separation processes and significantly reduce energy consumption in the chemical and petroleum industries, promoting more eco-efficient operations.
Lightnix Inc. is a Japanese company based in Nishinomiya that specializes in the development, manufacture, and sale of medical devices. Founded in 2002, the company focuses on innovative solutions to enhance patient care, particularly through its unique plant-based resin lancet needle. This product is designed to minimize pain during injections by mimicking the shape of a mosquito's proboscis, allowing for micro incisions with minimal needle exposure. Lightnix aims to provide a safer and less painful injection experience for patients, thereby improving overall healthcare outcomes.
Kinestral Technologies, Inc. specializes in manufacturing smart-tinting glass, branded as Halio, for both commercial and residential applications. Halio glass can transition from clear to tinted or dark, either automatically or on command, enhancing architectural design by providing versatile solutions for windows, walls, and skylights. This technology offers significant advantages over traditional electrochromic glass, including faster tinting, uniform coloration, and a natural appearance. Kinestral also provides a range of supporting products, such as the Halio Tint Selector, which allows localized control of window tinting, and Halio Cloud, an interface for integrating window operations with building automation systems. Founded in 2010 and headquartered in Hayward, California, Kinestral has established a strategic partnership with Asahi Glass Co., Ltd. Its advanced manufacturing techniques ensure reliable production and timely delivery for projects worldwide, ultimately aiming to improve energy efficiency and comfort in indoor environments.
Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrate for various applications in communications and industry. The company produces a range of products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, it offers broadband gain chips for ophthalmic testing equipment and retinal imaging laser eyewear. QD Laser's technology is applied in areas such as silicon photonics, sensing, and precision machining. The company serves a diverse clientele across telecommunications, manufacturing, medicine, and consumer products. Established in 2006, QD Laser is headquartered in Kawasaki, Japan.
Future Ink Corporation develops, manufactures, and markets printed electronics related products. It offers an n-type organic semiconductor material that is soluble in organic solvents. Future Ink Corporation was founded in 2016 and is based in Yonezawa, Japan.
Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, founded in 2005. The company specializes in the development of artificial chromosome technologies, which are utilized primarily for life sciences applications. By employing artificial chromosome vectors, Chromocenter focuses on advancing drug discovery processes, particularly in the field of medical pharmaceuticals. Its innovative approach aims to enhance the efficacy and efficiency of biopharmaceutical manufacturing, positioning the company at the forefront of next-generation therapeutic development.
Nanophoton Corporation specializes in the research, development, manufacture, and sale of advanced laser microscopy products. The company offers a range of instruments, including laser Raman microscopes, wide field Raman scopes, and tip-enhanced Raman microscopes. Additionally, it provides specialized equipment such as closed vessels for Raman spectroscopy of lithium-ion batteries, Z polarizers for three-dimensional measurements, and laser speckle reducers for enhanced microscope illumination. These products serve various industries, including semiconductors, secondary batteries, carbon materials, inorganic compounds, polymers, pharmaceuticals, and food applications. Nanophoton distributes its products globally through a network of representatives and distributors. Founded in 2003, the company is headquartered in Osaka, Japan.
Medicinal Chemistry Pharmaceuticals, Co., Ltd., founded in 2010 and headquartered in Sapporo, Japan, specializes in drug discovery and development services. The company focuses on creating innovative antibody drugs utilizing specialized glycotechnology. By providing disease-specific formulations of glycopeptides, it supports the development of high-quality seeds for drug discovery. This expertise is particularly valuable in the creation of antibodies aimed at cancer immunotherapy and the treatment of various diseases. The company's unique analytical technologies for sugar chain-related substances enhance its capabilities in the pharmaceutical sector.
Mu Lab Inc. is a company based in Fukushima, Japan, specializing in the design and development of advanced robotic technologies. The firm focuses on creating innovative robotic solutions to meet various needs in different sectors. By leveraging cutting-edge technology, Mu Lab aims to push the boundaries of robotics and enhance the capabilities of machines for practical applications.
Innophys Co., Ltd., founded in 2013 and based in Tokyo, Japan, specializes in wearable robotics technology. The company designs, manufactures, and distributes innovative robotics equipment aimed at various industries. Its flagship product, the Muscle Suit®, utilizes artificial muscle technology to provide physical assistance, reducing strain during tasks such as lifting heavy objects or working in bent positions. The Muscle Suit® is recognized for its high quality and competitive pricing compared to other exoskeletons in the market. Innophys aims to expand its reach into the Asia Pacific, European, and North American markets, enhancing the ability of users to perform tasks independently and improve their quality of life.
Spectronics is a development of new technologies and new applications to bring about innovation, focusing on the future of laser technology.
Cyfuse Biomedical develops tissue fabrication systems and cell-based products in Japan and internationally. The company offers 3D BioFabrication systems and related consumables; develops and licenses 3D tissue products for therapeutic and drug development use; and engages in contract manufacturing of 3D tissue products for research purposes.
Its products applications include blood vessel grafts for blood access of hemodialysis patients or coronary artery bypass grafts; cardiac grafts for drug toxicology screening or supplemental therapy of myocardial infarction; cartilage grafts for plastic surgery or reconstruction; and hepatocyte grafts for drug metabolism screening or in-vivo production of clotting factors in the treatment of hemophilia.
Cyfuse Biomedical was founded in 2010 and is based in Tokyo, Japan.
Quantum Biosystems Inc. specializes in quantum bio sequencing, focusing on the development of innovative single-molecule DNA and RNA sequencing systems. These systems are designed for comprehensive analysis of whole genomes, leveraging the principles of quantum mechanics to enhance sequencing capabilities. Founded on January 7, 2013, the company is headquartered in Yodogawa-ku, Japan. Through its advanced technology, Quantum Biosystems aims to improve the accuracy and efficiency of genomic analysis, contributing to advancements in the field of biotechnology.
NejiLaw is a high-performance industrial fastening members and fastening member performance evaluation tester / test room.NejiLaw prevents many of the accidents caused by screw fasteners as before, and further reduces the time required for construction and the economic benefits of reducing maintenance costs. Was born with the mission to bring.
NejiLaw is a high-performance industrial fastening members and fastening member performance evaluation tester / test room.NejiLaw prevents many of the accidents caused by screw fasteners as before, and further reduces the time required for construction and the economic benefits of reducing maintenance costs. Was born with the mission to bring.
SanBio Company Limited is a regenerative medicine firm based in Tokyo, Japan, focused on developing and commercializing cell-based therapies for various central nervous system disorders. The company is advancing its lead product, SB623, currently in Phase II clinical trials for treating chronic motor deficits caused by traumatic brain injury and stroke. SanBio's research pipeline also includes SB618 for peripheral nerve damage, SB308 for muscular dystrophy, and other products targeting conditions such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, spinal cord injuries, and Alzheimer’s disease. Collaborations with several academic institutions and partners, such as Asahikawa Medical University and Juntendo University, support the development of these therapies. Founded in 2001, SanBio aims to address unmet medical needs through innovative regenerative medicine solutions.
GlyTech, Inc. specializes in the manufacture of human type N-glycans and glycosylation technologies, as well as glycopeptide and glycoprotein synthesis. Established in 2012 and based in Kyoto, Japan, the company is dedicated to advancing the production of glycans and chemical glycosylation technologies for the development of innovative biopharmaceuticals and oligonucleotide therapeutics. GlyTech licenses glycosylated peptides and proteins and provides a range of services, including contract research and development, custom synthesis, and contract manufacturing. Additionally, the company engages in research collaborations and supplies standard reagents to support its partners in the pharmaceutical industry.
Advanced Photonics, Inc. is a Tokyo-based company established in 2006 that specializes in the development, design, manufacturing, and sale of optical circuit boards and related products. The company focuses on photoelectric conversion modules, which facilitate the mutual conversion of electric and optical signals, and optical printed circuit boards used for optical transmissions. By providing these innovative solutions, Advanced Photonics aims to support advancements in optical communication and interconnection technologies, offering clients reliable and cost-effective semiconductor options.
Micropelt is a startup that emerged from a collaborative project between Infineon Technologies AG and the Fraunhofer Institute for Physical Measurement Techniques in Germany. The company specializes in developing thin film thermoelectric components through semiconductor manufacturing processes. Micropelt focuses on creating energy-harvesting systems that integrate micro-actuators and sensors. Its product offerings include thermoelectric cooling chips and thermoelectric generators designed for various applications, such as chip spot cooling, biomedical devices, heating, ventilation, and air conditioning systems, as well as fiber optics. These innovations aim to facilitate effective temperature management in individual rooms while contributing to CO2 reduction and enhancing user comfort. The company has secured funding from several financial institutions, enabling its growth and development within the thin-film technology sector.
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
KinoPharma, Inc. is a Tokyo-based company founded in 2005 that specializes in the discovery and development of small molecule drugs targeting serine/threonine kinases. The company engages in collaborative research and development through partnerships with universities, focusing on creating clinical drugs with minimal side effects. KinoPharma leverages its expertise in phosphoenzyme inhibitor research to develop therapeutic agents for challenging conditions, including viral and neurodegenerative diseases. One of its key initiatives involves the creation of next-generation antiviral drugs aimed at addressing papillomavirus (HPV) infections in women, specifically targeting the prevention of cervical cancer.
NeoPhotonics offers a complete line of both active and passive optical components for every network market segment: FTTH/Access, Datacom, Storage Area Networks, Metro and Long Haul networks. NeoPhotonics' transceivers are compliant with industry standard MSAs, are available in GBIC, SFF, SFP, XFP and other configurations, and serve a variety of reaches, applications and data-rates from 155MBps to 10GBps. NeoPhotonics' advanced silica Planar Lightwave Circuit (PLC) integrated optical modules and subsystems are critical parts in access FTTH networks and in metro and long-haul DWDM networks. For FTTH, NeoPhotonics manufactures integrated splitters in high volume and FTTH BiDi and TriPlexer transceivers, Other products include AWGs, Athermal AWGs, VOA Multiplexers, EDFAs and ROADM Modules. NeoPhotonics' manufactures MEMS-based Variable Optical Attenuators and Dynamic Channel Equalizers
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
Nanotech Partners I Limited Partnership is a private equity fund dedicated to investing exclusively in the field of nanotechnology on a global scale. Established with the sponsorship of Mitsubishi Corporation, the fund aims to generate long-term capital gains for its investors, which include Mitsubishi Corporation, Mitsubishi Chemical Corporation, and Honjo Chemical Corporation. By targeting emerging nanotechnology businesses, the fund offers investors opportunities to capitalize on significant growth potential while providing them with insights into technology and commercialization processes. The management of the fund is handled by Nanotech Partners Limited, which operates with the assistance of Mitsubishi Corporation's overseas offices.